Spectrum Pharmaceuticals Inc. (SPPI)

8.86
NASDAQ : Health Technology
Prev Close 9.16
Day Low/High 8.77 / 9.37
52 Wk Low/High 6.22 / 21.80
Avg Volume 742.80K
Exchange NASDAQ
Shares Outstanding 104.06M
Market Cap 953.14M
EPS -1.20
P/E Ratio N/A
Div & Yield N.A. (N.A)
Spectrum Pharmaceuticals Highlights Four Abstracts On SPI-2012 And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS)

Spectrum Pharmaceuticals Highlights Four Abstracts On SPI-2012 And Poziotinib At The San Antonio Breast Cancer Symposium (SABCS)

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

Spectrum Pharmaceuticals And Onxeo Announce Complete Response In 67% Of Patients With Peripheral T-Cell Lymphoma In Combination Of Belinostat (Beleodaq®) And Standard CHOP

Spectrum Pharmaceuticals And Onxeo Announce Complete Response In 67% Of Patients With Peripheral T-Cell Lymphoma In Combination Of Belinostat (Beleodaq®) And Standard CHOP

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, and Onxeo S.

Spectrum Pharmaceuticals Highlights 18 Abstracts At The 57th Annual Meeting Of The American Society Of Hematology (ASH) In Orlando, Florida, December 5-8, 2015

Spectrum Pharmaceuticals Highlights 18 Abstracts At The 57th Annual Meeting Of The American Society Of Hematology (ASH) In Orlando, Florida, December 5-8, 2015

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced key presentations of...

First Week of SPPI January 2016 Options Trading

First Week of SPPI January 2016 Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the January 2016 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new January 2016 contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol To FDA As Part Of An Investigational New Drug (IND) Application For Poziotinib

Spectrum Pharmaceuticals Submits Phase 2 Breast Cancer Protocol To FDA As Part Of An Investigational New Drug (IND) Application For Poziotinib

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the Company has submitted...

Spectrum Pharmaceuticals Divests Rights To ZEVALIN® (ibritumomab Tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma

Spectrum Pharmaceuticals Divests Rights To ZEVALIN® (ibritumomab Tiuxetan) In Japan And Select Other Ex-US Countries To Mundipharma

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the divestment of ZEVALIN...

TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers

TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers

TheGrantLawFirm, PLLC announces that it filed a class action complaint ("Complaint") on behalf of all securities holders who purchased the securities of Spectrum Pharmaceuticals, Inc.

Short Interest Moves 14.3% Lower For SPPI

Short Interest Moves 14.3% Lower For SPPI

The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, which shows a 2,722,756 share decrease in total short interest for Spectrum Pharmaceuticals Inc , to 16,258,589, a decrease of 14.34% since 10/15/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Spectrum Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

INVESTOR ALERT: Brower Piven Encourages Shareholders Who Have Losses In Excess Of $100,000 From Investment In Spectrum Pharmaceuticals, Inc. To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the District of Nevada on behalf of purchasers...

Eagle Pharmaceuticals And Spectrum Pharmaceuticals Announce Co-Promotion Agreement

Eagle Pharmaceuticals And Spectrum Pharmaceuticals Announce Co-Promotion Agreement

Eagle Pharmaceuticals, Inc. (NASDAQ:EGRX) ("Eagle" or the "Company") and Spectrum Pharmaceuticals (NASDAQ:SPPI) ("Spectrum") today announced that they have entered into a co-promotion agreement ("the agreement") under which...

Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Third Quarter 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results...

TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers

TheGrantLawFirm, PLLC Files Class Action On Behalf Of Spectrum Pharmaceuticals, Inc. Securities Purchasers

TheGrantLawFirm, PLLC announces that it has filed a class action complaint ("Complaint") on behalf of all securities holders who purchased the securities of Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Third Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced it will host a...

Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial For The Treatment Of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement

Spectrum Pharmaceuticals Initiates Apaziquone Pivotal Trial For The Treatment Of Non-Muscle Invasive Bladder Cancer (NMIBC) Following SPA Agreement

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, announced today the Company has...

SHAREHOLDER ALERT: L & K Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Spectrum Pharmaceuticals, Inc. And Certain Officers And Directors

SHAREHOLDER ALERT: L & K Announces The Commencement Of An Investigation Involving Possible Securities Fraud Violations By Spectrum Pharmaceuticals, Inc. And Certain Officers And Directors

Levi & Korsinsky, LLP announces that it has commenced an investigation of Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) From U.S. Food And Drug Administration (FDA) For EVOMELA™ (melphalan) For Injection

Spectrum Pharmaceuticals Receives Complete Response Letter (CRL) From U.S. Food And Drug Administration (FDA) For EVOMELA™ (melphalan) For Injection

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today that it has received a...

Spectrum Pharmaceuticals (SPPI) Marked As A Dead Cat Bounce Stock

Spectrum Pharmaceuticals (SPPI) Marked As A Dead Cat Bounce Stock

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a "dead cat bounce" (down big yesterday but up big today) candidate

Spectrum Pharmaceuticals To Present Corporate Update At The Rodman & Renshaw 17th Annual Global Investment Conference On September 10th

Spectrum Pharmaceuticals To Present Corporate Update At The Rodman & Renshaw 17th Annual Global Investment Conference On September 10th

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of the...

Spectrum Pharmaceuticals Announces Publication Of Pivotal EVOMELA™ (melphalan Hydrochloride) For Injection Data In The Biology Of Blood And Marrow Transplantation Journal

Spectrum Pharmaceuticals Announces Publication Of Pivotal EVOMELA™ (melphalan Hydrochloride) For Injection Data In The Biology Of Blood And Marrow Transplantation Journal

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced publication of...

Spectrum Pharmaceuticals (SPPI) Strong On High Relative Volume Today

Spectrum Pharmaceuticals (SPPI) Strong On High Relative Volume Today

Trade-Ideas LLC identified Spectrum Pharmaceuticals (SPPI) as a strong on high relative volume candidate

Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals Announces Agreement With FDA On The Special Protocol Assessment (SPA) For The Upcoming Apaziquone Phase 3 Trial In Patients With Non-Muscle Invasive Bladder Cancer (NMIBC)

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations and a primary focus in Hematology and Oncology, announced today that the company has...

Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals Reports Second Quarter 2015 Financial Results And Pipeline Update

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, announced today financial results...

Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals Announces Second Quarter 2015 Financial Results Teleconference And Webcast

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced it will host a...

First Week of September 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of September 18th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the September 18th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new September 18th contracts and identified one put and one call contract of particular interest.

Spectrum Pharmaceuticals Stock Sees Short Interest Expand By 13.5%

Spectrum Pharmaceuticals Stock Sees Short Interest Expand By 13.5%

The most recent short interest data has been released by the NASDAQ for the 06/15/2015 settlement date, which shows a 2,743,537 share increase in total short interest for Spectrum Pharmaceuticals Inc , to 23,127,244, an increase of 13.46% since 05/29/2015. Total short interest is just one way to look at short data; another metric that we here at Dividend Channel find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares traded.

Spectrum Pharmaceuticals Announces Publication Of Beleodaq® Data Selected As A Rapid Communication In The Journal Of Clinical Oncology

Spectrum Pharmaceuticals Announces Publication Of Beleodaq® Data Selected As A Rapid Communication In The Journal Of Clinical Oncology

Spectrum Pharmaceuticals (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, announced today the publication of...

First Week of SPPI February 2016 Options Trading

First Week of SPPI February 2016 Options Trading

Investors in Spectrum Pharmaceuticals Inc saw new options begin trading this week, for the February 2016 expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 241 days until expiration the newly trading contracts represent a possible opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Spectrum Pharmaceuticals Highlights Five Abstracts Of Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, May 29-June 2, 2015

Spectrum Pharmaceuticals Highlights Five Abstracts Of Clinical Data At The 2015 American Society Of Clinical Oncology (ASCO) Annual Meeting In Chicago, Illinois, May 29-June 2, 2015

Spectrum Pharmaceuticals, Inc. (Nasdaq: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced presentations of...

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd

Spectrum Pharmaceuticals To Present Corporate Update At The Jefferies Global Healthcare Conference In New York City On June 3rd

Spectrum Pharmaceuticals, Inc. (NasdaqGS: SPPI), a biotechnology company with fully integrated commercial and drug development operations with a primary focus in Hematology and Oncology, today announced that an overview of...

First Week of July 17th Options Trading For Spectrum Pharmaceuticals (SPPI)

First Week of July 17th Options Trading For Spectrum Pharmaceuticals (SPPI)

Investors in Spectrum Pharmaceuticals Inc saw new options become available this week, for the July 17th expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the SPPI options chain for the new July 17th contracts and identified one put and one call contract of particular interest.

TheStreet Quant Rating: D (Sell)